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Bone marrow-derived cells (B cells),  1 i.e. the precursors of antibody-secreting 
cells, are distinguished by a dense coat of surface immunoglobulin able to bind 
antigen specifically (1-4). In addition,  an important subpopulation of B  cells 
(complement-receptor  lymphocytes  [CRL])  carries  membrane  receptors  for 
activated C3 capable of binding any antigen-antibody complex which functions 
as vehicle for C3b (5-8). 
It was recently proposed that  two distinct  signals  are required  for triggering B 
lymphocytes along the pathway of antibody formation:  (a)  the  specific binding of 
antigen to the immunoglobulin receptors and (b) the interaction of activated C3 with 
the complement receptors (9). In the context of this hypothesis it was postulated that 
release of proteases from stimulated  thymus-derived lymphocytes  (T  cells)  would 
generate active split products of C3 which could in turn bind to B lymphocytes, thus 
rendering them susceptible to activation by T-dependent antigens. The direct activa- 
tion of B cells by T-independent antigens (capable of elicifing an antibody response in 
the absence of thymus-derived cells) was thought to be linked to the presumed capacity 
of such molecules to activate C3 via the bypass mechanism. In fact, such a correlation 
seems to hold true for a number of T-independent antigens and B-cell mitogens.  * 
If B-cell activation depends on such a mechanism, one would predict not only that 
T-independent antigens should  be bypass activators, but also that bypass activators 
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might be effective B-cell mitogens and could substitute for the T-cell requirements of 
unrelated antigens, provided the bypass-inducing  substance  could bind in a  suitable 
way  to  B-cell membrane  components.  Moreover,  it would  be  expected  that  B-cell 
activation in vitro might depend on the availability of exogenous complement. 
In the work reported here we used purified cobra venom factor  (VF,  a  well 
defined and potent bypass  inducer  [10-12])  to test this hypothesis. 
Materials and Methods 
Mitogens.--VF  was  purified  chromatographically  from  lyophilized cobra  venom  (Naja 
Naja)  (Miami Serpentarium Labs,  Miami, Fla.)  by previously detailed methods  (12).  The 
final preparation contained approximately 3 pg protein per unit of activity (11). In order to 
exclude a contamination with lipopolysaccharides, the purified VF preparation was tested for 
pyrogenicity  in  rabbits  using  standard  pharmaceutical  procedures. 8  Coupling of VF  to 
Sepharose4B (Pharmacia, Uppsala, Sweden) was carried out as described before (13). SEPH- 
VF was suspended in an equal volume of veronal buffered saline (0.15 M, pH 7.4)  to give a 
concentration  of 0.6 mg bound  VF/ml. Phytohemagglutinin  P  (PHA,  Difco Laboratories, 
Detroit, Mich.), Concanavalin A (Con A, Calbiochem, San Diego, Calif.), pokeweed mitogen 
(PWM,  Grand Island Biological Corp.,  Grand Island, N. Y.), and lipopolysaccharide W  E. 
coli 0111: B4 (LPS, Difco) were obtained commercially. Except for SEPH-VF, 10 pl of mitogen 
dissolved in complete culture medium was added to the lymphocyte cultures at the beginning 
of the incubation period. 
Animals.--Specific pathogen-free mice of the lines nu/nu  (congenitally athymic "nude," 
fourth backcross generation with Balb/c), nu/+  =  (nu/nu  X  Balb/c)  F1,  and  C3CFI  = 
(C3H X  Balb/c) F1 were purchased from Bomholtg~ird,  Ry, Denmark and maintained in a 
barrier-sustained isolation unit. C5-deficient B10.D2-old/Sn mice and  Pirbright guinea pigs 
(GP) were obtained from Jackson Laboratory, Bar Harbor, Maine, and Tierfarm AG, Sisseln, 
Switzerland, respectively. Within each experiment test and control groups were matched for 
sex and age. 
Cell Suspensions.--Single  cell suspensions  for tissue culture experiments were prepared using 
standard  aseptic techniques (14). Cortisone-resistant thymus cells (crT) were obtained from 
6- to 8-wk old nu/+  donors which had been injected intraperitoneally with 125 mg/kg corti- 
sone acetate 48 h before (15). Lymph node cells (LNC) were prepared from pooled mesenteric, 
axillary, and  inguinal nodes of 8- to 12-wk  old nu/+  and nu/nu mice. Nu/nu LNC were 
filtered through a glass wool column in order to remove nonviable cells (14). Nu/+ and nu/nu 
LNC suspensions were contaminated with less than 1% mononuclear phagocytic cells, whereas 
spleen cell suspensions (SC) from 8- to 12-wk old nu/+ and nu/nu donors were found to con- 
tain 3.0  4- 0.9 and 7.4  4- 2.4% macrophages  (M), respectively (16).  M  were purified from 
gelatine-induced peritoneal exudates of 6- to 8-wk old nu/+  donors by adherence to plastic 
dishes (16). Thus, the different cell suspensions  provided sources of T and B cells, and of M as 
follows: crT =  T, nu/nuLNC =  B, nu/+ LNC =  T +  B, nu/nu SC =  B +  M, nu/+  SC  = 
T  +  B +  M, nu/+  adherent peritoneal cells =  M  (16). For rosette assays,  SC from 10- to 
12-wk old C3CFI mice and  mesenteric GP LNC from 7- to 8-wk old GP were prepared  as 
described elsewhere (5). 
Lymphocyte  Cultures.--In  order  to  assess  mitogen-induced  lymphocyte  proliferation, 
triplicate cultures of nu/+ crT and of nu/+ or nu/nu LNC were set up in disposable 12 X  75- 
mm tubes  (Falcon Plastics, Division of BioQuest, Oxnard,  Calif.) containing each 1 >(  l0 s 
8 Dietrich, F. M., R. H. Gisler,  C. Pericin, and G. Schumann. Proc. Soc. Exp. Biol. Md. 
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cells in 1-ml culture medium (Eagle's MEM for suspension cultures, Flow, Irvine, Scotland) 
modified as indicated by Mishell and Dutton  (17)  and supplemented with 8% fetal bovine 
serum (FBS) (Rehatuin, Reheis Chemical Co., Chicago, Ill). The tubes were kept at 37°C in a 
CO~  incubator (8%  COz  in air). Every 24 h, 60/ll of a  nutritive cocktail (14)  was added. 
16 h before harvest [6-SH]thymidine ([3H]T, 0.5/aCi/ml, sp act 23.3 Ci/mmol, Radiochemical 
Centre, Amersham, England) was added. TCA-precipitable radioactivity was measured using 
a liquid scintillation spectrometer. Results are expressed as counts per minute per tube. De- 
tails of the culture technique have been published before (14). 
Induction of antibody formation to SRBC in vitro was studied using the conditions indi- 
cated by Mishell and Dutton (17). Triplicate cultures of 1.5 X  107 nu/+  or nu/nu SC were 
set up in 35 X  10 mm disposable Petri dishes (Falcon Plastics) containing 1 ml of the same 
medium as used for the tube cultures, but supplemented with 10% FBS. Composite cultures 
(16) consisted of 3  X  106 nu/-[- crT and 7 X  10 s nu/nu LNC which were added to approxi- 
mately 3  X  105 adherent nu/q- peritoneal cells already attached to the dish. In some experi- 
ments, M  were omitted and the LNC cultured in the presence of 50 tbM 2-mercapto-ethanol 
(2-ME)  (18).  From the beginning, cultures were incubated with 3  X  10 s SRBC and assayed 
for 19S plaque-forming cells (PFC)  3-5 days later using the microslide method of Berglund 
(19). In the case of cultures containing sepharose, it was easily possible to distinguish between 
"true" hemolytic plaques produced by PFC and "false" plaques due to dislocation of SRBC 
in the agar gel by sepharose particles. True plaques were readily identified microscopically by 
the presence of nucleated cells in the center of a hemolytic area, whereas false plaques were 
much smaller and completely translucent with sharply defined contours. Moreover, if SEPH- 
VF was plated with SRBC in the absence of cultured cells, no true hemolytic plaques could be 
observed. 
Rosette Inhibition.--In order to study the possible interaction of activated C3 with CRL, 
SEPH-VF was converted with fresh mouse or GP serum to a  SEPH-VFSF enzyme complex 
capable of cleaving C3 in the absence of divalent cations (12): SEPH-VF was washed three 
times (centrifugation 2,800 g,  10 min, 4°C)  in excess medium RPMI  1640  (Grand Island). 
0.5-ml packed SEPH-VF were then incubated with 6 ml fresh serum at 37°C for 60 min in an 
immersion rotator, and washed again four times in excess RPMI 1640.5 X  106 C3CF1  SC in 
0.3 ml RPMI 1640 buffered with 28 mM HEPES  (Calbiochem) and adjusted to pH 7.6 were 
mixed with 0.2 ml fresh mouse plasma (collected in EDTA adjusted with NaOH to pH 7.6, 
final concentration 10 mM) and 0.1 ml packed SEPH-VFSF (mouse) in the presence of 10 mM 
EDTA. Similarly, 107 GP LNC (filtered through glass wool in order to remove nonviable cells) 
were  allowed  to  interact with fresh GP serum and  SEPH-VFSF  (GP)  in  the presence of 
EDTA. The tubes were incubated at 37°C  for 30 min by use of the immersion rotator. The 
cells were then washed three times in medium RPMI 1640 with HEPES, resuspended in the 
same medium, and the viability determined by a trypan blue exclusion test. Suspensions con- 
taining 90-95% viable cells were adjusted to a  cell density of 106/ml and allowed to form 
rosettes with SRBC which had been sensitized with rabbit amboceptor and C5-deficient serum 
from B  10. D2-old/Sn mice (EAC  1423).  Except for the use of C5-deficient serum  (dilution 
1:2 or 1:4), the preparations of EAC and the rosette assay for detection of CRL were carried 
out exactly as described by Bianco et al. (5). 
In another series of experiments, freshly prepared SC  and LNC  suspensions from 6-  to 
8-wk old C3CF1 or nu/nu mice were preincubated with native, heat-inactivated or zymosan- 
absorbed homologous serum, or with serum from VF-treated mice (see below),  l0  T LNC in 
0.3 ml medium RPMI 1640 were mixed with 0.2 ml serum in the presence or absence of 10 mM 
EDTA. Mter incubation at 37°C for 30 min in a waterbath, cells were washed three times in 
medium RPMI 1640 with HEPES and tested either for their rosette-forming capacity or for 
their proliferative potential in tissue culture. 
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FBS (zaFBS)  were all derived from the same frozen lot (see above).  For absorption, equal 
volumes of FBS and boiled and washed zymosan (Nutritional Biochemicals Corp., Cleveland, 
Ohio) were incubated at 37°C for 1 h with an immersion rotator. Mter centrifugation at 4°C 
(3000 g, 30 rain), absorbed FBS was stored at -80°C. The C3 content of the different FBS 
batches was  estimated by testing them with  GP complement  components  in  an immune 
hemolysis assay (20). Native FBS contained 3.7  X  10 ~ site-forming units C3 per ml.  This 
value was taken as 100%. Mter heat inactivation of the serum, 70% of the C3 was still avail- 
able, while after absorption with zymosan only 8.3%  C3 remained. 
Freshly collected mouse serum was heat inactivated or absorbed using the same conditions. 
In Vivo C3 Depletion.--In  order to obtain C3-depleted  mouse serum (21), 8- to 12-wk old 
C3CF1 mice received four intraperitoneal injections  of 0.2 mg/kg VF at 8-h intervals. Thus, 
the total dose administered to each animal over a 24-h period corresponded to approximately 
250 U of activity/kg. In some experiments control animals were treated with heat-inactivated 
(65°C, 30 rain) VF. All mice were bled 48 h afrer the last injection. 
RESULTS 
In a  first series of experiments, B-cell activation by VF was studied using a 
variety of culture systems. Since LPS preparations are known to be powerful 
stimulants of B-cell functions, possible contamination of VF with LPS had to 
be excluded first. For that purpose,  the relative pyrogenicity of graded doses 
of VF and LPS was compared in rabbits. Whereas as little as 0.1  #g/kg LPS 
intravenous produced a significant fever response, VF was not pyrogenic at the 
highest dose level tested  (10/~g/kg).  The  VF preparation used  was  thus not 
measurably contaminated with LPS. In lymphocyte cultures, VF was mitogenic 
for nu/+  LNC (T and B  cells) and for nu/+  crT (T cells), as well as for nu/nu 
LNC  (B  cells). Peak incorporation of [SH]T occurred on  the 3rd day (Fig. 1). 
Maximum responses were elicited at a  concentration  of  16 ~g VF/ml  culture 
fluid (Fig. 2). Similarly, SEPH-VF was found to be equally mitogenic for both 
T  and B  cells. 
In view of the marked B-cell activating properties of the two preparations, 
we sought to learn whether they could substitute for the role of T  cells in anti- 
body formation  to  a  predominantly  T-dependent  antigen.  Indeed,  in  T-cell 
deprived cultures,  VF  and  SEPH-VF  were  able to  restore responsiveness to 
SRBC. Thus,  soluble VF greatly increased the number of PFC in SC cultures 
from athymic donors (Fig. 3). SEPH-VF was even more effective. In order to 
minimize possible phagocytosis of SEPH-VF by M, almost pure B  cells (nu/nu 
LNC)  were  cultured in  the presence  of 2-ME,  which  is known  to  substitute 
operationally for M  (18). If SEPH-VF was added (together with SRBC) to such 
cells, plaque responses were observed, which were similar to or even greater than 
those obtained in composite cultures containing optimal numbers of T  and B 
cells and  2-ME  (Fig. 4).  On  the other hand,  both VF and  SEPH-VF had  an 
only moderate effect on the number of background PFC produced in cultures 
from which SRBC were omitted. Moreover, PFC production in T-cell sufficient 
SC cultures was not enhanced by the addition of VF. Some of these experiments 
are  shown  in  Fig.  5.  The  results  indicate,  that  the  effect  of  SEPH-VF  was DUKOR  ET AL,  341 
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FIG. 1. Time course of [SH]T  incorporation  into lymphocytes  stimulated with 16 jug VF/ml 
culture fluid (cpm per culture). Symbols  represent arithmetic means of triplicate cultures. 
antigen-related,  and  that,  at  least  in  the  model  system  employed,  the  VF 
preparations had functionally replaced the T  cells. 
If B-cell activation by VF and SEPH-VF were indeed linked to their pre- 
sumed  capacity of conferring activated C3  onto the  C3  receptor of CRL, it 
might be possible to demonstrate blocking of the complement receptor after 
interaction with the bypass-activating substance in the presence of C3. This 
question was  approached as follows:  the presence of functional complement 
receptors on B cells can be readily visualized by cluster formation of CRL with 
EAC (5). As will be shown below, the rosette-forming capacity of freshly pre- 
pared lymphocyte suspensions is inhibited by preincubation with C3-sufficient 
homologous serum, unless EDTA is added to the incubate. Since C3 activation 
by VF depends on the presence of Mg  ++, SEPH-VF had first to be converted 
with serum to give an enzyme capable of cleaving C3 in the absence of divalent 
cations  (SEPH-VFSF,  12).  Using  this  preparation,  we  studied  the  serum- 
dependent interaction of VF  with  CRL.  GP LNC  were preincubated in  the 
presence of EDTA with homologous serum and with SEPH-VFSF (GP). As is 
demonstrated in Table I, the ability of such cells to form rosettes upon subse- 
quent exposure to EAC 1423 was found to be greatly reduced. Similarly, a sig- 
nificant though less marked inhibition of rosette formation was obtained when 342  COMPLEMENT-DEPENDENT B-CELL  ACTIVATION.  .# 
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C3CF1 SC were preincubated with EDTA plasma from C5-deficient mice and 
SEPI-I-VFSF (mouse). The results suggest that SEPH-VF may be capable of 
conferring activated C3 onto C3 reactive lymphocytes. 
However,  if  SEPH-VFSF  and  EDTA  were  omitted  from  the  incubation 
mixture, fresh homologous serum by itself was found to completely suppress 
the rosette-forming ability of mouse and GP CRL. It was therefore interesting 
to  determine  whether  this  phenomenon  was  also  complement  dependent. 
C3CFz SC were incubated with differently pretreated sera from the same mouse 
strain  (final  concentration  1:5),  washed  extensively,  counted,  checked  for 
viability, diluted,  and then exposed to EAC. The results summarized in Table 
II demonstrate that the inhibitory effect of homologous serum was abolished 
by the addition of 10 mM EDTA, or by heat inactivation  (56°C,  30 min) or 
zymosan absorption. Likewise, pretreatment of the donors with VF (total dose 
250  U/kg)  48  h  before serum  collection  completely suppressed  the  blocking 
capacity of mouse serum. Injection of donor mice with heat-inactivated (65°C, 
30 min) VF was ineffective (data not shown in Table II). 
Similar results  4 were obtained with SC and LNC from various mouse strains, 
including nu/nu lymphoid cells,  and with SC and LNC from GP. Serum from 
4 Dukor, P., H. ]?robst, and D. Bitter-Suermann. Manuscript in preparation. DUKOR  ET AL.  343 
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FIG. 3. Reconstitution by VF of the 19S PFC response to SRBC in T-ceU-deprived SC cul- 
tures. O--O: 1.5 X  107 nu/-t-  SC; ($--$)  1.5 X  107 nu/nu SC with 4 or 16 pg of VF; 
(@- -@) 1.5 X 107 nu/nu SC without VF. Symbols represent arithmetic means of triplicate 
cultures. 
CS-deficient B10.D2-old/Sn mice was just as effective as sera from other donor 
strains.  GP  serum and  FBS,  on  the  other hand,  failed to interfere  with  the 
rosette-forming  potential  of  mouse  lymphoid  cells.  However,  the  rosette- 
forming ability of GP lymphocytes was readily inhibited  by GP serum. The 
results indicate that homologous serum is activated in vitro (by freshly prepared 
lymphoid cell suspensions) to block the C3 receptor of B lymphocytes, provided 
a  zymosan-removable or VF-sensitive component,  a  heat-labile serum factor, 
and divalent cations are present. Consequently it seemed worthwhile to explore 
whether the proliferative capacity of B  cells could be altered by pretreatment 
with homologous serum. Nu/nu LNC were incubated under aseptic conditions 
with different types of sera as described above, and cultured in the presence of 
different doses of Con A, an otherwise T-cell-specific mitogen (22). As is shown 
in Table III, preincubation with fresh homologous serum resulted in a  small, 
but  definite  increase  in  the  proliferative  response.  Heat-inactlvated  or 
zymosan-absorbed serum,  or serum from VF-treated mice proved ineffective. 
The data are compatible with the idea that B  cells can respond to a T-cell- 
specific mitogen, provided a serum component such as cleaved C3 is conferred 344  COMPLEMENT-DEPENDENT  B-CELL ACTIVATION~ 
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Fro. 4. Reconstitution by SEPH-VF of the 19S PFC response to SRBC in T-cell-deprived 
LNC cultures in the presence of 50/~M 2-ME. (0--0) 7 X  106 nu/nu LNC with graded 
doses of SEPH-VF; (O--O) 7 X 106 nu/nu LNC +  3 X 106 nu/+ crT without SEPH-VF; 
7 X l0 s nu/nu LNC without SEPH-VF; (e - -  e) 7 )< 106 nu/nu LNC with 20 pl sepharose. 
Symbols represent arithmetic means of triplicate cultures. 
to their C3 receptor sites by an additional mechanism. If this were true, it would 
also have to be postulated that B-cell activation in vitro might depend on a 
sufficient supply of exogenous complement components. In order to check this 
prediction,  nu/+  crT,  nu/+  LNC,  and  nu/nu  LNC  were  cultured  in  the 
presence  of  native  or  hiFBS,  or  of zaFBS  (C3  content  100,  70  and  8.3%, 
respectively). Although zaFBS did not interfere with the PHA-, VF-, or Con A- 
induced proliferation of T  cells, it clearly failed to sustain the proliferative re- 
sponse of B  cells to the B-cell activating mitogens PWM (22),  LPS (23),  VF, 
and SEPH-VF (Table IV). HiFBS, on the other hand, allowed B-cell prolifera- 
tion to proceed normally. A selective toxicity of zymosan-absorbed serum for B 
cells  appears unlikely,  since cell  recoveries were  the same in both  FBS- and 
zaFBS-supplemented nu/+  or nu/nu LNC cultures.  Moreover, as is demon- 
strated in Table V, nu/nu SC, but not nu/nu LNC, could be readily stimulated 
by LPS in the presence of zaFBS. 
These  results  suggest that  a  zymosan-removable serum factor is necessary DI6KOR  ET  AL.  345 
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FIG. 5. Effect of VF and SEPH-VF on the 19S PFC response to SRBC in T-cell-sufficient 
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TABLE I 
Inhibition  of Rosette Formation by GP LNC Exposed to SEPH-VFSF, GP Serum, and EDTA 
Preincubation  treatment* 
EAC rosette-forming cells,~ exp. no. 
1  2  3 
%  %  % 
Control medium  24.5  ±  1.7  32.8  -4-  4.1  31.0  -4-  0 
Seph-VFSF  20.5  -4-  5.1  27.0  -4-  2.4 
GP serum  19.5  -4-  2.4  25.3  -4-  3.6  28.6  -4-  6.8 
Seph-VFSF and GP  5.0  -4-  1.0  10.3  -4-  0.7  5.8  -4-  1.7 
serum 
* 30 min, 37 °, 10 mM EDTA. 
Mean values of triplicates or quadruplicates  4- SD. 
for  the  mitogen-induced  proliferation  of B  cells,  and  that  this factor may  be 
substituted  by  a  constituent  present  in  SC  suspensions.  Somewhat  different 
results  were  obtained  when  the  serum-dependence  of  antibody  responses  was 
investigated in a  composite culture  system  (16):  antibody formation  to SRBC 
in vitro (Table V1) could be elicited only if native or heat-inactivated FBS was 
added to the medium. Anti-SRBC responses in the presence of either T  cells or 346  COMPLEMENT-DEPENDENT  B-CELL ACTIVATION? 
TABLE  :IX 
Inhibition  of  Rosette Formation  by  C3CF~ SC  Exposed  to  Complement-Suff~vient arid 
Complement-Depleted Homologous Serum 
Preincubation treatment* 
EAC rosettedorming cells$ and exp. no. 
1  2  3 
Control medium 
Native mouse serum 
Native mouse serum, 
10 mM EDTA 
Heat-inactivated 
mouse serum 
Zymosan-absorbed 
mouse serum 
Serum from VF- 
treated mice 
%  %  % 
20.6  4-  1.2  18.0  4-  0  14.3  4-  1.0 
0.7  4-  0.3  0.5  ±  0.3  0 
22.4  4-  1.8 
20.6  ±  1.3 
21.3  4-  3.8 
14.3  4-  2.4 
* 30 min, 37 °. 
:~ Mean values of triplicates or quadruplicates 4- SD. 
TABLE  III 
Proliferation of Serum-Prdncubated B Cells (nu/nu LNC) Stimulated by Con A 
Preincubation treatment* 
Stimulation index day 3:~ 
Con A 1 #g/ml  Con A 4 #g/ml 
Controlmedium  1.2  4-  0.1  (8)§  0.8  4-  0.1  (8) 
Native mouse serum  5.9  4-  0.2  (10)  7.4  ±  0.1  (I0) 
Heat-inactivated mouse  1.2  4-  0.2  (3)  1.2  4-  0.8  (5) 
serum 
Zymosan-absorbed mouse  1.1  4-  0.1  (4)  1.4  4-  0.8  (5) 
serum 
Serum from VF-treated mice  1.1  4-  0.2  (3)  1.3  4-  0.2  (3) 
* 30 min, 37 °. 
[aH]T incorporation: experimental/controls, mean values 4-  SE. 
§ Number of triplicate cultures. 
T-cell  substituting  mitogens  (LPS,  VF,  SEPH-VF)  did  not  occur  in  culture 
medium  supplemented  with  zaFBS  irrespective  of  the  source  of  the  B  cells 
(SC  or LNC)  and the presence or absence of M. 
DISCUSSION 
The  results  presented  in  this  communication  demonstrate  (a)  that  highly 
purified, pyrogen-free VF is strongly mitogenic for mouse T  and B  cells; (b) that 
VF,  and  even  more  effectively,  SEPH-VF,  restore  the  potential  of  antibody 
formation to SRBC  in mouse B-cell cultures; (c) that SEPH-VF  in the presence 
of  complement  may  block  the  capacity  of  lymphocytes  to  form  rosettes  with DUKOR  ET  AL.  347 
TABLE IV 
Serum Requirements of Mitogen-Induced Lymphocyte Proliferation 
[3HIT incorporation*; medium supplemented with: 
Cells  Mitogen  Exp. 1  Exp. 2 
8% FBS  8% hiFBS  8% zaFBS  8% FBS  8% zaFBS 
Nu/+ crT 
Nu/+ LNC 
None  1,522 
PHA  16  31,784 
VF  16 
None  1,341 
Con A  4  54,938 
PHA  16  21,298 
VF  16 
LPS  16 
Nu/nu LNC  None  563  205 
VF  16 
Seph-VF  20~  3,254  1,862 
LPS  16  24,634  18,330 
PWM  16  5,996  6,335 
cpm/culture day 3 
454  105  69 
21,393  12,457  11,594 
3,042  3,738 
988  320  265 
55,358 
29,491  11,124  11,728 
34,642  4,655 
7,805  682 
321  615  241 
9,730  388 
349 
546  8,688  701 
360 
* Mean values of triplicate cultures. 
/~1 suspension added per culture. 
TABLE V 
Serum Requirements of Mitogen-lnduced B-Cell Proliferation in LNC and SC Cultures 
[SH]T incorporation*; medium supplemented with: 
Cells  Mitogen  Exp. 1  Exp. 2 
8% FBS  8% zaFBS  8% FBS  8% zaFBS 
LNC nu/nu 
SC nu/nu  None 
LPS 16 
~ml  cpm/culture day3 
None  358  278  563  321 
LPS 16  7,261  552  24,634  546 
758  321  1,034  191 
24,638  5,468  24,310  3,268 
* Mean values of triplicate cultures. 
EAC;  (d)  that preincubation of freshly prepared B-cell suspensions with  C3- 
sufficient, but not with C3-depleted homologous serum also inhibits their sub- 
sequent interaction with EAC and at the same time renders them reactive to 
an otherwise T-cell-specific mitogen (Con A); (e)  that mitogen-induced B-cell 
proliferation  and  T-cell  mediated  or  mitogen-triggered  antibody  formation 
against SRBC appear to depend on the availability of a serum factor which can 
be removed by zymosan; and (f) that in some culture systems this factor may 348  COMPLEMENT-DEPENDENT  B-CELL  ACTIVATION? 
TABLE VI 
Serum  Requirements for Reeonstitution by B-Cell Mitogens of T Cell-Deprived Cultures: PFC 
Response to SRBC 
Cells 
19S PFC/culture day 4* 
Mitogen  Medium supplemented with: 
10g FBS  10% hiFBS  10% zaFBS 
Nu/+ SC:~ 
Nu/nu SC 
~g/r~t 
None  8,480  7,455  530 
None  45 
LPS  4  1,340  945  185 
LPS  12  3,085  3,111  240 
VF  4  570  665  50 
VF  16  2,350  2,060  125 
SEPH-VF  40  7,240  180 
M B  None  170 
M§ TH B¶ 
B(+2=ME)** 
None  10,545  8,930  665 
LPS  12  2,875  2,340  245 
VF  16  1,210  1,005  90 
None  85 
SEPH-VF  405:~  6,360  415 
* Mean values of triplicate cultures. 
:~ 15 ×  107 cells. 
§3 X 105 nu/+M. 
[] 3 X 10 6 nu/+crT. 
¶ 7 X 10 6 nu/nu LNC. 
** 50 pM. 
:~$ pl suspension added per culture. 
be substituted by a constituent present in SC suspensions. The interdependence 
of these phenomena is not yet clear. It is nevertheless  tempting to speculate 
that  they may be linked by a  common mechanism and  to interpret  them in 
terms of the complement-hypothesis of B-cell activation (Fig. 6). 
It is obvious that the signal for cell proliferation is provided by the way in 
which  a  mitogen  interacts  with  the  lymphocyte membrane.  In  this  respect, 
mitogen-induced cell triggering is thought to represent a model for immunocyte 
activation by antigens. It has been postulated that different epitope densities 
are required for effective stimulation of T  and B  cells  (24).  It is also possible 
that  antigenic determinants  or the  reactive groups of a  mitogen have  to be 
attached to a suitably rigid or poorly degradable backbone in order to become 
B-cell activators. Some support for the local concentration hypothesis of B-cell 
activation  was furnished  by the  finding  that  locally concentrated mitogens, 
such as sepharose-coupled PHA (25),  or Con A bound to a plastic surface (26), DLTKOR ET AL.  349 
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FIO. 6. Model of complement-mediated B-cell activation by T-dependent (liB m) and T- 
independent (~) antigens. B cells are triggered by the simultaneous or sequential generation 
of two signals, one antigen-related, one nonspecific.  Generation of the specific signal depends 
on the appropriate interaction of the antigen with corresponding immunoglobulin  receptors 
on the B cell membrane (Y), necessitating  in the case of T-dependent antigens  complexing  with 
T-cell receptors (V) which may be released and bind to the surface of macrophages (M)  (24). 
The nonspecific signal involves the binding of activated C3 (w) to the C3 receptor (~j) of B 
lymphocytes. C3 (0) may be activated by T-independent antigens, or by nonspeciiic factors 
(proteases ?) released from antigen-stimulated  T cells or macrophages (,~,~:, A) (9). 
are  capable  of  stimulating B  cells,  whereas  the mitogenicity of  the  soluble 
material is restricted to T cells (22). On the other hand, a very different property 
appears actually to be shared by a number of representative B-cell activators: 
B-cell mitogens such as VF, LPS, PWM, and dextran sulfate (27), but not the 
T-cell-specific  mitogens PHA and Con A, were found to be capable of initiating 
the alternative pathway of C3  activation. Similarly, T-independent antigens 
including Pneumococcus Type III polysaccharide, levan, polymerized flagellin, 
dinitrophenylated dextran, and, again, LPS were found to activate and convert 
C3 in C4-deficient GP serum, and to convert C3 and C3 proactivator in human 
serum.~ 
B-cell-activating molecules might therefore be able to confer cleaved C3 to 
the C3 receptors of the B cells to which they are bound, thus providing them 
with  an  essential nonspecific signal for triggering and/or proliferation. It is 
evident that not all bypass activators could be expected to be B-cell mitogens, 
since mitogenicity as such is likely to depend on suitable cross-linking of lympho- 
cyte membrane components by the mitogenic agent. On the other hand, mito- 
gens are known to interact with lymphocytes nonspecifically. The binding of 
mitogenic agents is therefore not restricted to the limited number of immuno- 
cytes  bearing  complementary  immunoglobulin  receptors.  Hence,  bypass- 
activating mitogens may also interact with B cells which at the same time bind 
an unrelated antigen. If this antigen is T dependent, i.e. incapable of activating 
C3  by itself, the bypass-inducing mitogens may now provide cleaved C3  re- 
quired to initiate specific antibody formation. Indeed, as shown above, VF and 
SEPH-VF are able to substitute operationally for T  cells in an otherwise pre- 350  COMPLEMENT-DEPENDENT  B-CELL ACTIVATION? 
dominantly T-dependent antibody response. Similar effects have been observed 
with PWM, 5 LPS (28), dextran sulfate (29), and polymerized flagellin (30). It 
is of course quite possible that the T-cell substituting effect of these agents is a 
direct consequence of their B-cell mitogenicity, as has recently been suggested 
by Sj6berg et al.  (28). Moreover, M  activation by B-cell mitogens or cross- 
reactivity between VF or PWM and SRBC have not yet been formally excluded. 
Our results have further demonstrated that bypass activators may indeed be 
capable of conferring activated C3 to the C3 receptors of B cells: in the absence 
of divalent cations, preincubation of lymphocytes with homologous serum or 
plasma and SEPH-VFSF blocked their capacity to subsequently form rosettes 
with EAC  1423. In fact, preincubation of fresh lymphocyte suspensions with 
homologous serum in the presence of divalent cations was also found to inhibit 
rosette  formation  completely.  Similar  observations  (release  of  cell-bound 
antigen-antibody complement complexes in  the presence of serum)  were re- 
cently made by Miller and Nussenzweig (31). Competitive blocking of the C3 
receptor in these systems seems to depend on a factor from freshly prepared 
(excited?)  lymphocytes  (or  macrophages),  on  divalent  cations,  on  a  heat- 
labile factor which was shown to be C3 proactivator (31), and on a zymosan- 
removable and VF-sensitive component, most likely C3. In the presence of all 
these required factors, C3 may be activated and conferred to the C3 receptor 
site of CRL. Indeed,  "blocked" cells can be agglutinated by antimouse-/~lc, 
indicating the presence of C3 on their membranes  4. Rosette inhibition may thus 
prove to be  a  useful  tool for the  detection of cell-associated mouse  comple- 
ment components. 
The increased responsiveness of serum-pretreated B cells to stimulation with 
Con A, which was also demonstrated in this communication, is reminiscent of 
the acquisition of Con A reactivity by B cells in the presence of a supernatant 
factor from T-cell cultures (32). Since it is possible that activated T  cells or 
macrophages may release a  C3  cleaving enzyme (9),  both sets of  data  are 
compatible with the idea that B cells can respond to a T-cell-specific mitogen, 
provided cleaved C3 is conferred to the complement receptor of CRL by an 
additional mechanism. 
Finally,  we  have  shown  that  mitogen-induced  B-cell  activation  in  LNC 
cultures and antibody formation to SRBC in composite cultures containing T 
cells or T-cell-substituting mitogens takes place only in the presence of normal 
or heat-inactivated, but not of zymosan-absorbed serum. Recent observations 
indicate  that  the  same  is  true  for  the  T-independent  antibody response  to 
dinitrophenylated dextran.  5 The C3  content of the untreated or heat-inacti- 
vated FBS correlates well with the proposed C3 requirements of B-cell activa- 
tion by VF, PWM, and LPS. The strongly reduced C3 content of the zymosan- 
absorbed  serum  and  its  failure  to  permit  B-cell  proliferation  and  antibody 
5 Gisler,  R. H., G.  Schumann, and P. Dukor, unpublished observation. DUKOR  ET AL.  351 
production would also fit into the picture, even though it should be noted that 
absorption with zymosan removes not only C3 but various other serum factors 
involved in the  bypass activation of the  complement system. On  the  other 
hand, at least the C3 proactivator was certainly destroyed by heating the sera 
(33) and thus the bypass activation of C3 should not take place according to the 
data typically obtained with the conventional hemolytic assay for C3. It there- 
fore remains to be explained why the presumed C3 proactivator-depleted serum 
still allows B-cell activation to occur. The following possibilities might be con- 
sidered: (a) the cellular system is very sensitive and can be triggered already by 
a  degree of bypass activation which can hardly be detected by a  hemolytic 
assay for C3 turnover, (b) the cells replenish the system with the needed factors 
either by release or by having them absorbed to their surface, or (c)  the pro- 
liferation and antibody formation induced by VF and LPS do not depend on 
the cofactors as defined for the bypass in vitro but rely on a yet unknown re- 
action mechanism which also leads to activation of C3. These possibilities are 
now under investigation. 
Our findings indicate further that the requirement for an exogenous supply 
of zymosan-removable serum factors (C3?) is by no means absolute, since in 
SC  cultures mitogen-induced B-cell  proliferation  was  sustained by zaFBS. 
Indeed, using different culture conditions, SC responded to stimulation with 
LPS even in the total absence of serum (34). Mitogen-induced B-cell prolifera- 
tion and polyclonal antibody formation in serum-free SC cultures was also ob- 
served by Coutinho et al. (35).  It may be pertinent in this context that SC 
suspensions are known to contain a much greater proportion of macrophages 
than LNC (16),  and that macrophages have been reported to synthesize or to 
carry complement components including C3 (36). In fact, recent evidence from 
our laboratory suggests that nonadherent SC can be stimulated by LPS only 
in the presence of serum, whereas mitogenic B-cell activation in unfractionated 
SC cultures is serum independent) It will have to be explained, nevertheless, 
why in our systems zaFBS consistently failed to support antibody formation in 
vitro, irrespective of the presence of adherent SC or of peritoneal macrophages. 
Preliminary data  indicate  that  culture  tube-adsorbed  serum  components 
may very effectively substitute for fluid phase serum factors (34). It might be 
possible, therefore, that under physiological conditions cell surface-associated 
complement components play an important role in cell triggering. This may be 
relevant to the observation that in vivo C3 depletion by VF in mice was found 
to inhibit T-dependent, but not T-independent antibody formation (21),  and 
that a patient suffering from homozygous C3 deficiency had apparently normal 
serum-immunoglobulin levels (37).  Although the data presented in this com- 
munication do not directly prove any of the assumptions of the complement 
hypothesis of B-cell activation, they nevertheless appear to be compatible with 
it and encourage further experimentation. 352  COMPLEMENT-DEPENDENT  B-CELL ACTIVATION? 
SUMMARY 
It has been proposed that two distinct  signals  are required for the triggering 
of the precursors of antibody-forming  bone marrow-derived cells  (B cells):  (a) 
the binding of antigen or of a mitogen to the corresponding receptor  sites  on B- 
cell  membranes and (b) the interaction  of activated C3 with the C3 receptor of 
B lymphocytes. There is  growing evidence that B-cell  mitogens and T (thymus- 
derived  ccll)-independent antigens are capable  of activating the alternate 
pathway of the complement system (bypass). Therefore, the effect  of another 
potent bypass inducer was investigated  with regard to B-cell  activation  and the 
role  of C3. Purified,  pyrogcn-iree cobra venom factor  was mitogcnic for both T 
and B  lymphocytcs  (cortisone-resistant  mouse thymus cells  and lymph node 
lymphocytes from congenitally athymic mice). Venom factor could substitute 
for T cells  by restoring  the potential  of antibody formation to sheep red blood 
cells  in mouse B-cell  cultures  supplemented with macrophagcs or 2-mercapto- 
ethanol. Venom factor may bc capablc of con/erring activated C3 to the C3 
receptor of B  lymphocytcs: prcincubation of lymphoid cells  with homologous 
serum or plasma,  I0 mM  EDTA,  and sepharose-coupled venom  factor con- 
vertcd with scrnm to an enzyme active against C3, inhibited  their  capacity to 
subsequently form rosettes  with sheep erythrocytes sensitized  with amboceptor 
and CS-dcficient  mouse complement. In the absence ol EDTA,  prcincubation 
of  freshly  prepared B-cell  suspensions with C3-suf~cient  homologous serum also 
blocked their  subsequent interaction  with complement-sensitized  erythrocytes 
and at the same time rendered them reactive to an otherwise T-cell-specific 
mitogcn. Moreover, mitogen induced B-cell  proli/eration in lymph node (but 
not in spleen)  cell  cultures,  appeared to depend on the availability  of exogenous 
C3: zymosan-absorbed  fetal  bovine  serum (only 8.3  %  site-forming  units re- 
maining) supported T-cell  activation  by phytohemagglutinin,  concanavalin A, 
and venom factor,  but failed  to  sustain  B-cell  stimulation  by pokeweed mitogen, 
lipopolysaccharide, and venom factor.  T-cell-dependent antibody formation in 
composite cultures containing T cells  or T-cell-substituting  B-cell  mitogcns, B 
cells,  and macrophages, always required the presence of C3-sufficient serum. 
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